Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease

被引:62
作者
Samaee, Hamidreza [1 ]
Mohsenzadegan, Monireh [2 ]
Ala, Shahram [1 ]
Maroufi, Shahnam Sedigh [3 ]
Moradimajd, Parisa [3 ]
机构
[1] Mazandaran Univ Med Sci, Dept Clin Pharm, Fac Pharm, Sari, Iran
[2] Iran Univ Med Sci, Fac Allied Med Sci, Dept Med Lab Sci, Tehran, Iran
[3] Iran Univ Med Sci, Fac Allied Med Sci, Dept Anesthsia, Tehran, Iran
关键词
Tocilizumab; COVID-19; Coronavirus disease; Actemra;
D O I
10.1016/j.intimp.2020.107018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The coronavirus disease 2019 (COVID-19) virus has spread all over the world. Scientists are trying to discover drugs as effective treatment for patients with COVID-19. So far about 30 drugs have been introduced that one of them is Tocilizumab. Recently Tocilizumab has been introduced to treat patients with COVID-19 and researchers are investigating further the efficacy of this drug for different are patients. In Iran and China, some reports showed a positive effect of Tocilizumab on Saturation of Peripheral Oxygen (SPO2) but results of CT scan in patients in different. In some patients, CT scan showed reduced infiltration, however in other no change was observed. Unfortunately, until now there has been no definitive and effective treatment for patients with COVID-19. Although Tocilizumab has been accepted by China Health Commission to treat infected patients, its positive effects still cannot be predicted in all patients. Based on evidence of the Tocilizumab's effect on the SARS COV 2, researchers hope this drug will make effective and promising treatment to improve lung tissue inflammation in patients with the fatal COVID-19 virus. The present study provides an overview of respiratory inflammation with COVID-19 and probable effect of Tocilizumab on SARS-COV 2.
引用
收藏
页数:7
相关论文
共 42 条
[41]   Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [J].
Yang, Xiaobo ;
Yu, Yuan ;
Xu, Jiqian ;
Shu, Huaqing ;
Xia, Jia'an ;
Liu, Hong ;
Wu, Yongran ;
Zhang, Lu ;
Yu, Zhui ;
Fang, Minghao ;
Yu, Ting ;
Wang, Yaxin ;
Pan, Shangwen ;
Zou, Xiaojing ;
Yuan, Shiying ;
Shang, You .
LANCET RESPIRATORY MEDICINE, 2020, 8 (05) :475-481
[42]   Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients [J].
Zhou, Yonggang ;
Fu, Binqing ;
Zheng, Xiaohu ;
Wang, Dongsheng ;
Zhao, Changcheng ;
Qi, Yingjie ;
Sun, Rui ;
Tian, Zhigang ;
Xu, Xiaoling ;
Wei, Haiming .
NATIONAL SCIENCE REVIEW, 2020, 7 (06) :998-1002